; (ii) improve the sensitivity of Lyme disease tests at all stages of disease progression; (iii) develop a Lyme disease test capable of distinguishing between past and active infections; (iv) improve timely, sensitive, and specific diagnostic tools and tests for Rocky Mountain spotted fever; and (v) improve the performance (timeliness and accuracy) of tools and tests for other tick-borne diseases found in the United States. (B) Strategies for expediting clearance The Secretary shall direct the Commissioner of Food and Drugs to design and propose or implement, as appropriate within the authorities and public health priorities vested in the Secretary by other provisions of law, strategies for facilitating and expediting the clearance or approval of improved diagnostic tests for Lyme disease and other tick-borne disease, particularly where— (i) there are no cleared diagnostic tests; or (ii) cleared diagnostic tests lack a high level of specificity or sensitivity or are unable to confirm the presence or absence of active infection. (3) Ensuring safety and efficacy of vaccines The Secretary shall— (A) ensure the safety and efficacy of any new, renewed, or modified human vaccine for Lyme disease, other tick-borne disease, or a combination of such diseases